Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Other Working Capital Changes (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Other Working Capital Changes for 11 consecutive years, with -$1.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Working Capital Changes fell 996.82% year-over-year to -$1.3 million, compared with a TTM value of -$113250.0 through Sep 2025, down 213.89%, and an annual FY2024 reading of -$46500.0, down 8062.33% over the prior year.
  • Other Working Capital Changes was -$1.3 million for Q3 2025 at Kiora Pharmaceuticals, down from $1.2 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $1.2 million in Q2 2025 and bottomed at -$1.3 million in Q3 2025.
  • Average Other Working Capital Changes over 5 years is -$7810.4, with a median of -$8073.0 recorded in 2021.
  • The sharpest move saw Other Working Capital Changes surged 1722.95% in 2022, then plummeted 996.82% in 2025.
  • Year by year, Other Working Capital Changes stood at -$48463.0 in 2021, then surged by 385.84% to $138526.0 in 2022, then fell by 28.22% to $99438.0 in 2023, then plummeted by 146.76% to -$46500.0 in 2024, then tumbled by 2731.72% to -$1.3 million in 2025.
  • Business Quant data shows Other Working Capital Changes for KPRX at -$1.3 million in Q3 2025, $1.2 million in Q2 2025, and $39226.0 in Q1 2025.